Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies.

Autor: Navarro-Compán V; V. Navarro-Compán, MD, PhD, MSc, Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain., Rudwaleit M; M. Rudwaleit, MD, University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany., Dubreuil M; M. Dubreuil, MD, MSc, Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA., Magrey M; M. Magrey, MD, Case Western Reserve University, University Hospitals, Cleveland, Ohio, USA., Marzo-Ortega H; H. Marzo-Ortega, LMS, PhD, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK., Mease PJ; P.J. Mease, MD, Swedish Medical Center and Providence St. Joseph Health and University of Washington, Seattle, Washington, USA., Walsh JA; J.A. Walsh, MD, Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, Utah, USA., Dougados M; M. Dougados, MD, PhD, Department of Rheumatology, Hôpital Cochin, University of Paris Cité, Paris, France., de la Loge C; C. de la Loge, MSc, Brussels, Belgium., Fleurinck C; C. Fleurinck, MD, UCB, Brussels, Belgium., Massow U; U. Massow, PhD, UCB, Monheim am Rhein, Germany., Vaux T; T. Vaux, MSc, UCB, Slough, UK., Taieb V; V. Taieb, MSc, UCB, Colombes, France., Deodhar A; A. Deodhar, MD, MRCP, Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA.

Publikováno v: The Journal of rheumatology [J Rheumatol] 2024 Oct 15. Date of Electronic Publication: 2024 Oct 15.

Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.

Autor: Dubreuil M; Department of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA mdubreui@bu.edu., Navarro-Compán V; Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain., Boonen A; Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands.; Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, The Netherlands., Gaffney K; Norfolk and Norwich University Hospital NHS Trust, Norfolk, UK., Gensler LS; Department of Medicine/Rheumatology, University of California San Francisco, San Francisco, California, USA., de la Loge C; UCB Pharma, Brussels, Belgium., Vaux T; UCB Pharma, Slough, UK., Fleurinck C; UCB Pharma, Brussels, Belgium., Massow U; UCB Pharma, Monheim am Rhein, Germany., Taieb V; UCB Pharma, Colombes, France., Mørup MF; UCB Pharma, Copenhagen, Denmark., Deodhar A; Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA., Rudwaleit M; University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany.

Publikováno v: RMD open [RMD Open] 2024 Jun 04; Vol. 10 (2). Date of Electronic Publication: 2024 Jun 04.

Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.

Autor: Baraliakos X; Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany Xenofon.Baraliakos@elisabethgruppe.de., Deodhar A; Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA., van der Heijde D; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Magrey M; University Hospitals, Case Western Reserve University, Cleveland, Ohio, USA., Maksymowych WP; Department of Medicine, University of Alberta Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada., Tomita T; Graduate School of Health Science, Morinomiya University of Medical Sciences, Osaka City, Osaka, Japan., Xu H; Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China., Massow U; UCB Pharma, Monheim am Rhein, Germany., Fleurinck C; UCB Pharma, Brussels, Belgium., Ellis AM; UCB Pharma, Raleigh, North Carolina, USA., Vaux T; UCB Pharma, Slough, UK., Shepherd-Smith J; UCB Pharma, Slough, UK., Marten A; UCB Pharma, Monheim am Rhein, Germany., Gensler LS; Department of Medicine/Rheumatology, University of California San Francisco, San Francisco, California, USA.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2024 Jan 11; Vol. 83 (2), pp. 199-213. Date of Electronic Publication: 2024 Jan 11.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.